A team of researchers from the Laboratory of Biophysics at NUST MISIS, Lomonosov Moscow State University and D. Mendeleev University of Chemical Technology of Russia has summarized metal-containing diagnostic agents for positron emission tomography (PET), magnetic resonance imaging (MRI), and single-photon emission computed tomography (SPECT) imaging of Alzheimer's disease (AD). According to the researchers, metal-containing radiopharmaceuticals are not only highly effective for detecting early markers of Alzheimer's disease, but also synchrotron-independent and long-lived. Thus, their use could improve access to diagnostic imaging of AD among the risk groups. The review was published in the International Journal of Molecular Sciences.
Alzheimer's disease is the most common form of dementia. It is a progressive neurological disease that leads to a decline in memory and other cognitive abilities. AD is associated with the deposition of so-called amyloid protein plaques in the brain that disrupt communication among neurons, resulting in loss of function and cell death. Amyloid plaques are a hallmark of AD, occurring 7-15 years before the onset of cognitive symptoms of the pathology. They allow doctors to diagnose Alzheimer's earlier -- even before any symptoms appear.
Timely diagnostic imaging plays an important role in managing AD. Identifying it at an early stage and initiating therapy can delay the progression of the disease. Amyloid deposits in the brain can be PET-traced using special radioactive markers that bind to different amyloids. However, using these drugs requires an expensive laborious synthesis with confirmation of radio purity at each stage. The short half-lives of the currently used radionuclides carbon-11 (11C) and fluorodeoxyglucose (18F) -- 20 and 109 minutes respectively -- may also limit the widespread use of these imaging agents, since they can only be transported a short distance before use and have to be used immediately upon arrival.
Numed, a well established company in business since 1975 provides a wide range of service options including time & material service, PM only contracts, full service contracts, labor only contracts & system relocation. Call 800 96 Numed for more info.
The solution could lie in metal-containing diagnostical agents. Copper, zinc and iron cations have been proven to bind to amyloids, highlighting amyloid plaques, which raises the possibility of designing copper-, zinc and iron-based metal complexes for the diagnosis and theranostics of AD. AD diagnostic agents radiolabeled with the copper isotope 64Cu are attractive not only due to the simple and fast introduction of radionuclide at the last stage of non-radioactive synthesis, but also due to its 12-hour half-life, perfect for PET imaging.